Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of General Surgery, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.
J Med Virol. 2022 Oct;94(10):4890-4900. doi: 10.1002/jmv.27962. Epub 2022 Jul 5.
To determine the safety and efficacy profile of teenager COVID-19 vaccination. In this retrospective cohort study, contact numbers of parents of teenagers under 18 years of age referred to a teenager vaccination centers in Tehran-Iran to receive the corona vaccine were collected, and the following information was obtained via the phones: demographic information, type of vaccine, and the number of doses received, as well as additional information like complications and required treatments. Eleven thousand forty-two subjects aged 10-18 years, mean age 14.55 ± 1.83 year including 5374 boys and 5768 girls were investigated. 88.1% received the Sinopharm and 11.9% the Soberana vaccine. General side effects, including fatigue, fever and chills, injection site pain and dizziness, and so forth happened in 2978 cases; 7421 children presented with at least one general or organ-specific side effect following vaccination, including potentially critical side effects, such as vascular injuries, respiratory complication, and so forth. 0.1% of the subject needed hospital admission. The breakthrough infection happened in 200 individuals. Our study shows that Sinopharm and Soberana (PastoCoVac) COVID-19 vaccines are generally safe with no serious side effects in less than 18 years old. COVID-19 infection and reinfection can occur after vaccination, but the incidence is actually tolerable and significantly lower than in the unvaccinated group.
确定青少年接种 COVID-19 疫苗的安全性和疗效概况。在这项回顾性队列研究中,收集了伊朗德黑兰青少年疫苗接种中心预约接种疫苗的 18 岁以下青少年父母的联系号码,并通过电话获取以下信息:人口统计学信息、疫苗类型和接种剂量,以及并发症和所需治疗等其他信息。
研究对象为 10-18 岁的 11042 名受试者,平均年龄为 14.55±1.83 岁,其中包括 5374 名男孩和 5768 名女孩。88.1%的人接种了国药疫苗,11.9%的人接种了苏贝兰疫苗。2978 例出现一般副作用,包括疲劳、发热和发冷、注射部位疼痛和头晕等;7421 例儿童在接种后出现至少一种一般或器官特异性副作用,包括血管损伤、呼吸并发症等潜在严重副作用。0.1%的受试者需要住院治疗。200 人发生突破性感染。
我们的研究表明,国药和苏贝兰(Pastocovac)COVID-19 疫苗在 18 岁以下人群中通常是安全的,没有严重的副作用。接种疫苗后仍可能发生 COVID-19 感染和再感染,但发病率实际上是可以耐受的,且明显低于未接种疫苗的人群。